Source-grounded facts extracted from Canton Strategic Holdings, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Canton Strategic Holdings, Inc. amended Sales Agreement with Clear Street LLC and Virtu Americas LLC valued at $300,000,000 (effective 2026-03-03).
“On March 3, 2026, Canton Strategic Holdings, Inc. (the " Company "), entered into an amended and restated sales agreement (the " Sales Agreement ") with Clear Street LLC (" Clear Street ") and Virtu Americas LLC (" Virtu ", and together with Clear Street, the " Sales Agents "), relating to the sale of shares of the Company’s common stock”
Canton Strategic Holdings, Inc.: Bylaws amended to reflect name change and current size of Board of Directors (effective 2026-02-18).
“The Company also amended and restated its bylaws on February 18, 2026 to reflect the Name Change and reflect the current size of the Board of Directors.”
Canton Strategic Holdings, Inc.: Name change from Tharimmune, Inc. to Canton Strategic Holdings, Inc., approved via amended and restated certificate of incorporation (effective 2026-02-09).
“On February 18, 2026, Tharimmune, Inc. (the “ Company ”) changed its corporate name to “Canton Strategic Holdings, Inc.,” pursuant to an amended and restated certificate of incorporation filed with the Delaware Secretary of State on February 9, 2026”
Canton Strategic Holdings, Inc. entered into Underwriting Agreement with Clear Street LLC valued at Gross proceeds approximately $55 million; offering of 1,800,000 shares of common stock at $2.9200 pe (effective 2026-01-20).
“On January 20, 2026, Tharimmune, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Clear Street LLC, as the sole underwriter (the “Underwriter”), relating to an underwritten registered offering to a single institutional investor (the “Offering”) of (i) 1,800,000 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at an offering price of $2.9200 (the “Offering Price”), and (ii) certain pre-funded warrants (the “Pre-Funded Warrants”), at an offering price of Offering Price less $0.0001 per Pre-Funded Warrant, to purchase up to 17,000,000 shares of Common Stock.”
Canton Strategic Holdings, Inc. received a nasdaq deficiency notice notice regarding board independence (rules 5605).
“January 9, 2026, Tharimmune, Inc. (the “Company”) received a notification letter from The Nasdaq Stock Market LLC regarding its noncompliance with Nasdaq Listing Rule 5605 (“Rule 5605”), which requires, among other things, that a majority of the Board of Directors of the Company (the “Board”) be comprised of independent directors. As previously disclosed, Nancy Davis and Sanam Parikh resigned as members of the Board, effective as of November 6, 2025 and Mark Wendland was elected to replace Sanam Parikh, resulting in one vacancy on the Board and the noncompliance. In accordance with Nasdaq List”
Canton Strategic Holdings, Inc. issued warrant to certain accredited investors (the Cryptocurrency Purchasers) for $3.075 less $0.0001.
“On November 3, 2025, the Company entered into securities purchase agreements (the " Cryptocurrency Securities Purchase Agreements ," and together with the Cash Securities Purchase Agreements, the " Securities Purchase Agreements ") with certain accredited investors (the " Cryptocurrency Purchasers ," and together with the Cash Purchasers, the " Purchasers ") pursuant to which the Company agreed to sell and issue to the Cryptocurrency Purchasers in a private placement (the " Cryptocurrency Offering ," and together with the Cash Offering, the " Offerings ") (i) pre-funded warrants (" Cryptocurrency Pre-Funded Warrants " and, together with the Cash Pre-Funded Warrants, the " Pre-Funded Warrants ") to purchase shares of Common Stock (" Cryptocurrency Pre-Funded Warrant Shares " and, together with the Cash Pre-Funded Warrant Shares, the " Pre-Funded Warrant Shares ") at an offering price of $3.075 less $0.0001”
Canton Strategic Holdings, Inc. issued warrant to certain accredited investors (the Cash Purchasers) for offering price of the Per Share Cash Purchase Price less $0.0001 per Cash Pre-Funded Warrant.
“and/or pre-funded warrants (the " Cash Pre-Funded Warrants ") to purchase shares of the Common Stock (the " Cash Pre-Funded Warrant Shares " and together with Cash Pre-Funded Warrants, the " Cash Securities ") at an offering price of the Per Share Cash Purchase Price less $0.0001 per Cash Pre-Funded Warrant”
Canton Strategic Holdings, Inc. issued an aggregate offering of either shares of common stock of common stock to certain accredited investors (the Cash Purchasers) for $3.075 per Cash Share.
“On November 3, 2025, Tharimmune, Inc. (the " Company ") entered into securities purchase agreements (the " Cash Securities Purchase Agreements ") with certain accredited investors (the " Cash Purchasers ") pursuant to which the Company agreed to sell and issue to the Cash Purchasers in a private placement offering (the " Cash Offering ") an aggregate offering of either shares (the " Cash Shares ") of common stock of the Company, par value $0.0001 per share (the " Common Stock ") at an offering price of $3.075 per Cash Share”
Canton Strategic Holdings, Inc.: Increased authorized shares of Common Stock from 250,000,000 to 1,000,000,000 (effective 2025-10-10).
“On October 10, 2025, Tharimmune, Inc. (the “Company”) filed a Certificate of Amendment (the “Amendment”) to its Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware pursuant to which it increased the total number of shares of Common Stock authorized for issuance thereunder from 250,000,000 shares to 1,000,000,000.”
Kelly Anderson resigned as Director at Canton Strategic Holdings, Inc..
“On June 22, 2025, Kelly Anderson resigned from the Board of Directors of Tharimmune, Inc. for personal reasons, effective immediately.”
Don Kim resigned as Chief Financial Officer at Canton Strategic Holdings, Inc..
“On June 10, 2025, Don Kim, Chief Financial Officer of Tharimmune, Inc. (the “Company”) resigned from his position as CFO for personal reasons, effective immediately.”
James Gordon Liddy was appointed as Director at Canton Strategic Holdings, Inc..
“the Board appointed James Gordon Liddy as a member of the Board, effective immediately.”
Sireesh Appajosyula was appointed as Chief Executive Officer at Canton Strategic Holdings, Inc..
“the Board appointed Sireesh Appajosyula as the Company’s Chief Executive Officer, effective immediately.”
Randy Milby resigned as Chief Executive Officer and Director at Canton Strategic Holdings, Inc..
“Randy Milby pursuant to which he resigned for personal reasons from his positions as Chief Executive Officer and member of the Board of Directors, effective immediately.”
Randy Milby changed role as Chairman of the Board at Canton Strategic Holdings, Inc..
“Mr. LoPriore shall replace Randy Milby who served as Chairman of the Board.”
Vincent LoPriore was appointed as Executive Chairman at Canton Strategic Holdings, Inc..
“On May 9, 2025, the Board of Directors (the “Board”) of Tharimmune, Inc. (the “Company”) appointed Vincent LoPriore, a director of the Company, as Executive Chairman of the Board, effective immediately.”
Gary Stetz was appointed as member of the Board at Canton Strategic Holdings, Inc..
“On April 28, 2025, the Board of Directors (the “Board”) of Tharimmune, Inc. (the “Company”) increased the size of the Board to nine members and appointed each of Clay Kahler and Gary Stetz as members of the Board.”
Clay Kahler was appointed as member of the Board at Canton Strategic Holdings, Inc..
“On April 28, 2025, the Board of Directors (the “Board”) of Tharimmune, Inc. (the “Company”) increased the size of the Board to nine members and appointed each of Clay Kahler and Gary Stetz as members of the Board.”
Vincent LoPriore was appointed as member of the Board at Canton Strategic Holdings, Inc..
“appointed Vincent LoPriore as a member of the Board.”
Don Kim was appointed as Chief Financial Officer at Canton Strategic Holdings, Inc..
“appointed Don Kim as Chief Financial Officer of the Company, effective as of March 27, 2025.”
Thomas Hess resigned as Chief Financial Officer at Canton Strategic Holdings, Inc..
“accepted the resignation of Thomas Hess as Chief Financial Officer of the Company, effective as of March 26, 2025.”
Canton Strategic Holdings, Inc. shareholders approved Approval of Tharimmune, Inc. Amended and Restated 2023 Omnibus Equity Incentive Plan at the 2024-05-14 meeting.
“Proposal 4. The Tharimmune, Inc. Amended and Restated 2023 Omnibus Equity Incentive Plan was approved by the stockholders by the votes set forth in the table below: For Against Abstain Broker Non Vote 2,405,905 551,134 5,882 1,984,343”
Canton Strategic Holdings, Inc. shareholders approved Grant of discretionary authority to Board to amend Certificate of Incorporation to effect reverse stock split within range 1-for-2 to 1-for-50 at the 2024-05-14 meeting.
“Proposal 3. The grant of discretionary authority to the Company’s Board of Directors to (A) amend the Company’s Certificate of Incorporation, as amended, to effect one or more consolidations of the issued and outstanding shares of common stock of the Company pursuant to which the shares of common stock would be combined and reclassified into one share of common stock at a ratio within the range from 1-for-2 up to 1-for-50 (the “Reverse Stock Split”) and (B) arrange for the disposition of fractional interests by stockholders entitled thereto by entitling such stockholders to receive from the Company’s transfer agent, in lieu of any fractional share, the number of shares of common stock rounded up to the next whole number, provided that, (X) that the Company shall not effect Reverse Stock Splits that, in the aggregate, exceeds 1-for-50, and (Y) any Reverse Stock Split is completed no later than May 14, 2025, was approved by the stockholders by the votes set forth in the table below: For”
Canton Strategic Holdings, Inc. shareholders approved Ratification of Rosenberg Rich Baker Berman P.A. as independent registered public accounting firm for fiscal year 2024 at the 2024-05-14 meeting.
“Proposal 2. The appointment of Rosenberg Rich Baker Berman P.A., as the Company’s independent registered public accounting firm for its fiscal year ended December 31, 2024 was ratified and approved by the stockholders by the votes set forth in the table below: For Against Abstain Broker Non Vote 4,800,694 123,028 23,541 1”
Canton Strategic Holdings, Inc. shareholders approved Election of five directors at the 2024-05-14 meeting.
“Proposal 1 . All of the five (5) nominees for director were elected to serve until the 2025 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, or until such director’s earlier resignation, removal or death. The result of the votes to elect the five (5) directors was as follows: Directors For Against Abstain Broker Non Vote Randy Milby 2,871,156 0 91,765 1,984,343”
Canton Strategic Holdings, Inc.: Lowered quorum requirement for stockholder meetings from a majority to one-third of shares entitled to vote (effective 2024-03-07).
“The Amendment amends and restates in its entirety Article II, Section 2.6 of the Bylaws to lower the quorum requirement for stockholder meetings from requiring the holders of a majority of the Company’s stock issued and outstanding and entitled to vote to be present in person or represented by proxy to one-third of the holders of the Company’s stock issued and outstanding and entitled to vote to be present in person or represented by proxy.”
Canton Strategic Holdings, Inc.: Filing of Certificate of Amendment to effect a 1-for-25 reverse stock split (effective 2023-11-20).
“On November 17, 2023, Tharimmune, Inc. (the “Company”) filed a Certificate of Amendment (the “Amendment”) to its Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware pursuant to which it effected a 1-for-25 reverse stock split of its issued and outstanding shares of common stock (the “Reverse Split”).”
Canton Strategic Holdings, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5550(b)(1)).
“September 30, 2023, the Company reported stockholders’ equity of $1,756,923, which is below the Stockholders’ Equity Requirement for continued listing. Additionally, as of the date of the Letter, the Company did not meet either of the alternative Nasdaq continued listing standards under the Nasdaq Listing Rules, which include a market value of listed securities of at least $35 million or net income of $500,000 from continuing operations in the most recently completed fiscal year, or in two of the three most recently completed fiscal years. The Letter has no immediate effect on the listing of t”
Canton Strategic Holdings, Inc. entered into Avior Patent License Agreement with Avior Inc. d/b/a Avior Bio, LLC valued at $24,250,000 (effective 2023-11-03).
“Tharimmune, Inc. (the “Company”) entered into a patent license agreement (the “Avior Patent License Agreement”) with Avior Inc. d/b/a Avior Bio, LLC (“Avior”)”
Canton Strategic Holdings, Inc. shareholders approved Approval of discretionary authority to effect reverse stock split within range from 1-for-2 to 1-for-50 at the 2023-10-23 meeting.
“Proposal 4 . At the Annual Meeting, the stockholders approved granting discretionary authority to the Company’s board of directors to (A) amend the Company’s Certificate of Incorporation, as amended, to effect one or more consolidations of the issued and outstanding shares of common stock of the Company pursuant to which the shares of common stock would be combined and reclassified into one share of common stock at a ratio within the range from 1-for-2 up to 1-for-50 (the “Reverse Stock Split”) and (B) arrange for the disposition of fractional interests by stockholders entitled thereto by entitling such stockholders to receive from the Company’s transfer agent, in lieu of any fractional share, the number of shares of common stock rounded up to the next whole number, provided that, (X) that the Company shall not effect Reverse Stock Splits that, in the aggregate, exceed 1-for-50, and (Y) any Reverse Stock Split is completed no later than October 23, 2024. The result of the votes to appr”
Canton Strategic Holdings, Inc. shareholders approved Approval of the 2023 Omnibus Equity Incentive Plan at the 2023-10-23 meeting.
“Proposal 3 . At the Annual Meeting, the stockholders approved the Company’s 2023 Omnibus Equity Incentive Plan (the “2023 Plan”). The result of the votes to approve the 2023 Plan was as follows: For Against Abstain Broker Non-Votes 8,129,962 375,606 2,470 2,429,777”
Canton Strategic Holdings, Inc. shareholders approved Ratification of the appointment of Rosenberg Rich Baker Berman P.A. as independent registered public accounting firm for fiscal year 2023 at the 2023-10-23 meeting.
“Proposal 2 . At the Annual Meeting, the stockholders approved the ratification of the appointment of Rosenberg Rich Baker Berman P.A. (“RRBB”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The result of the votes to approve RRBB was as follows: For Against Abstain 10,732,062 203,030 2,723”
Canton Strategic Holdings, Inc. shareholders approved Election of five nominees for director at the 2023-10-23 meeting.
“Proposal 1 . At the Annual Meeting, five nominees for director were elected to serve until the next annual meeting of stockholders or until their respective successors have been duly elected and qualified, or until such director’s earlier resignation, removal or death. The result of the votes to elect the five directors were as follows: Directors For Abstain Broker Non-Votes Randy Milby 8,314,605 193,390 2,429,820 Leonard Mazur 8,358,930 149,108 2,429,777 Lynne A. Bui 7,823,648 684,390 2,429,777 Sireesh Appajosyula 8,313,024 194,971 2,429,820 Kelly Anderson 8,315,552 192,486 2,429,777”
Canton Strategic Holdings, Inc.: Company changed its name from Hillstream BioPharma, Inc. to Tharimmune, Inc. via a Certificate of Amendment to its Certificate of Incorporation (effective 2023-09-25).
“On September 21, 2023, Hillstream BioPharma, Inc. (the “Company”) filed a Certificate of Amendment (the “Amendment”) to its Certificate of Incorporation, as amended (the “Certificate of Amendment”), with the Secretary of State of the State of Delaware pursuant to which it changed its name to Tharimmune, Inc. effective as of September 25, 2023.”
Canton Strategic Holdings, Inc. engaged Rosenberg Rich Baker Berman P.A. as its auditor.
“on July 12, 2023, the Committee approved the appointment of Rosenberg Rich Baker Berman P.A. (“RRBB”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 effective as of July 12, 2023, replacing Mayer Hoffman McCann P.C.”
Canton Strategic Holdings, Inc. entered into ABSI Agreement with Applied Biomedical Science Institute (ABSI) valued at $250,000 (effective 2023-07-05).
“On July 5, 2023 (the “ABSI Effective Date”), Hillstream BioPharma, Inc. (the “Company”) entered into a Research and Development Collaboration and License Agreement (the “ABSI Agreement”) with Applied Biomedical Science Institute (“ABSI”) pursuant to which ABSI granted the Company an exclusive royalty-bearing, sublicensable license to the ABSI Patents”
Sireesh Appajosyula was appointed as Chief Operating Officer at Canton Strategic Holdings, Inc..
“On July 6, 2023, the Board appointed Sireesh Appajosyula, the Company’s director, as Chief Operating Officer of the Company effective immediately.”
Canton Strategic Holdings, Inc. reported that prior financial statements should not be relied upon.
“the Company, after discussion with its audit committee concluded that its previously issued audited financial statements for the year ended December 31, 2022 and unaudited financial statements for the quarters ended March 31, 2022, June 30, 2022 and September 30, 2022 should be restated and no longer be relied upon”
Mayer Hoffman McCann P.C. resigned as auditor of Canton Strategic Holdings, Inc..
“On June 14, 2023, Mayer Hoffman McCann P.C. ("MHM"), the independent registered public accounting firm of Hillstream BioPharma, Inc. (the "Company"), provided the Company notice of its resignation as the Company's independent registered public accounting firm effective as of the earlier of: (i) the date the Company appoints a new independent registered public accounting firm; (ii) the date the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 is filed with the Securities and Exchange Commission ("SEC"); and (iii) August 19, 2023.”
Canton Strategic Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“June 12, 2023, Hillstream BioPharma, Inc. (the “Company”) received written notice (the “Notice”) from the Nasdaq Stock Market, LLC (“Nasdaq”) indicating that the bid price for the Company’s common stock (the “Common Stock”), for the last 30 consecutive business days, had closed below the minimum $1.00 per share and, as a result, the Company is not in compliance with the $1.00 minimum bid price requirement for the continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2). The Notice has no effect at this time of the Common Stock, which continues to trade on”
Canton Strategic Holdings, Inc. reported that prior financial statements should not be relied upon.
“ctivities and is considered a material change to the financial statements requiring the Company to restate its December 31, 2022 audited financial statements and its unaudited financial statements for the quarters ended March 31, 2022, June 30, 2022 and September 30, 2022 on Form 10-K/A. As such, the previously issued audited financial statements for the year ended December 31, 2022 and unaudited financial statements for the quarters ended March 31, 2022, June 30, 2022 and September 30, 2022 (collectively, the “ Period”) should no longer be relied upon as the Company did not correctly account for the financed insurance premium. The restatement will have an effect on the Company’s previously reported audited balance sheet as of December 31, 2022 and its unaudited balance sheets and statements of”
Kelly Anderson was appointed as Director at Canton Strategic Holdings, Inc..
“On May 9, 2023, the Board of Directors (the “Board”) of Hillstream BioPharma, Inc. (the “Company”) increased the size of the Board to five members and appointed Kelly Anderson as a member of the Board to fill the vacancy created by the increase in the size of the Board.”
Canton Strategic Holdings, Inc. entered into Underwriting Agreement with ThinkEquity LLC, as representative of the several underwriters listed on Schedule 1 thereto valued at approximately $2.2 million (effective 2023-04-27).
“On April 27, 2023 (the “Effective Date”), Hillstream BioPharma, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with ThinkEquity LLC (“ThinkEquity”), as representative of the several underwriters listed on Schedule 1 thereto (the “Underwriters”), relating to the public offering (the “Offering”) of 5,300,000 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a price to the public of $0.50 per Share (the “Offering Price”).”
Canton Strategic Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“October 27, 2022, Hillstream BioPharma, Inc., a Delaware corporation (the “ Company ”), received written notice (the “ Notice ”) from the Nasdaq Stock Market, LLC (“ Nasdaq ”) indicating that the bid price for the Company’s common stock (the “Common Stock”), for the last 30 consecutive business days, had closed below the minimum $1.00 per share and, as a result, the Company is not in compliance with the $1.00 minimum bid price requirement for the continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2). The Notice has no effect at this time of the Common S”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.